The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Phase 1 trial of CAR T-cell therapy for lymphoma
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s National Medical Center, Washington, DC, discusses the initial analysis of a phase 1 dose-escalation study of activated autologous CD30-specific chimeric antigen receptors (CAR) T cells infused in patients with relapsed or refractory CD30-positive Hodgkin lymphoma or non-Hodgkin lymphoma.
